Nestlé S.A. (SWX:NESN) is discussing a potential sale of its peanut allergy medicine to Swiss health-care group Stallergenes Greer Ltd, people with knowledge of the matter said. Stallergenes has been holding talks with Nestlé about a possible deal for the Palforzia treatment, the people said, asking not to be identified discussing confidential information.
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
- EUR | -.--% |
|
+0.14% | +29.68% |
2023 | Nestle Reportedly May Sell Peanut Allergy Therapy to Stallergenes | CI |
2023 | Stallergenes Greer Ltd Initiates European Paediatric Phase III Study with Staloral Birch | CI |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
93.64 CHF | +0.86% | +1.21% | 271B | ||
- EUR | -.--% | +0.14% | 0 | ||
1st Jan change | Capi. | |
---|---|---|
+29.68% | 0 | |
+4.82% | 71.18B | |
+30.13% | 9.61B | |
+27.03% | 4.73B | |
-20.42% | 4.53B | |
+17.61% | 3.68B | |
+8.68% | 1.96B | |
-38.78% | 2.03B | |
-38.87% | 1.81B | |
-45.08% | 1.71B |
- Stock Market
- Equities
- STAGR Stock
- News Stallergenes Greer
- Nestle Reportedly May Sell Peanut Allergy Therapy to Stallergenes